Telomerase and HER-2/neu as targets of genetic cancer vaccines in dogs

Vaccine

Volumn 28, Issue 5, 2010, Pages 1201-1208

  Peruzzi, Daniela ^a   Mesiti, Giuseppe ^a   Ciliberto, Gennaro ^a   La Monica, Nicola ^a   Aurisicchio, Luigi ^a  

^a IRBM   (Italy)

Author keywords

Adenovirus; DNA EP; Tumor immunity; Vaccination

Indexed keywords

CANCER VACCINE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CANCER GENETICS; CANCER IMMUNIZATION; CONTROLLED STUDY; DOG; DRUG TARGETING; ELECTROPORATION; IMMUNE RESPONSE; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; SEROTYPE;

ADAPTIVE IMMUNITY; ADENOVIRIDAE; ANIMALS; CANCER VACCINES; DOG DISEASES; DOGS; ELECTROPORATION; FEMALE; HUMANS; IMMUNIZATION; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; RECEPTOR, ERBB-2; TELOMERASE;

EID: 74149094270     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.11.031     Document Type: Article

References (41)

1. Aurisicchio L., Mennuni C., Giannetti P., Calvaruso F., Nuzzo M., Cipriani B., et al. Immunogenicity and safety of a DNA prime/adenovirus boost vaccine against rhesus CEA in nonhuman primates. Int. J. Cancer 120 11 (2007) 2290-2300
2. Babiuk S., Baca-Estrada M.E., Foldvari M., Storms M., Rabussay D., Widera G., et al. Electroporation improves the efficacy of DNA vaccines in large animals. Vaccine 20 27-28 (2002) 3399-3408
3. Scheerlinck J.P., Karlis J., Tjelle T.E., Presidente P.J., Mathiesen I., and Newton S.E. In vivo electroporation improves immune responses to DNA vaccination in sheep. Vaccine 22 13-14 (2004) 1820-1825
4. Zucchelli S., Capone S., Fattori E., Folgori A., Di Marco A., Casimiro D., et al. Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer. J. Virol. 74 24 (2000) 11598-11607
5. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415 6869 (2002) 331-335
6. Stephenson J. Defective adenoviruses as novel vaccines for the Flaviviridae. Clin. Diagn. Virol. 10 2-3 (1998) 187-194
7. Casimiro D.R., Bett A.J., Fu T.M., Davies M.E., Tang A., Wilson K.A., et al. Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J. Virol. 78 20 (2004) 11434-11438
8. Casimiro D.R., Chen L., Fu T.M., Evans R.K., Caulfield M.J., Davies M.E., et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 77 11 (2003) 6305-6313
9. Yang Z.Y., Wyatt L.S., Kong W.P., Moodie Z., Moss B., and Nabel G.J. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J. Virol. 77 1 (2003) 799-803
10. Paoloni M., and Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat. Rev. Cancer 8 2 (2008) 147-156
11. Argyle D.J., and Nasir L. Telomerase: a potential diagnostic and therapeutic tool in canine oncology. Vet. Pathol. 40 1 (2003) 1-7
12. Nasir L. Telomeres and telomerase: biological and clinical importance in dogs. Vet. J. 175 2 (2008) 155-163
13. Nasir L., Devlin P., McKevitt T., Rutteman G., and Argyle D.J. Telomere lengths and telomerase activity in dog tissues: a potential model system to study human telomere and telomerase biology. Neoplasia 3 4 (2001) 351-359
14. Yazawa M., Okuda M., Setoguchi A., Iwabuchi S., Nishimura R., Sasaki N., et al. Telomere length and telomerase activity in canine mammary gland tumors. Am. J. Vet. Res. 62 10 (2001) 1539-1543
15. Yazawa M., Okuda M., Setoguchi A., Nishimura R., Sasaki N., Hasegawa A., et al. Measurement of telomerase activity in dog tumors. J. Vet. Med. Sci. 61 10 (1999) 1125-1129
16. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 4785 (1987) 177-182
17. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 4905 (1989) 707-712
18. Gama A., Alves A., and Schmitt F. Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classification. Virchows Arch. 453 2 (2008) 123-132
19. Facciabene A., Aurisicchio L., Elia L., Palombo F., Mennuni C., Ciliberto G., et al. Vectors encoding carcinoembryonic antigen fused to the B subunit of heat-labile enterotoxin elicit antigen-specific immune responses and antitumor effects. Vaccine 26 1 (2007) 47-58
20. Rizzuto G., Cappelletti M., Maione D., Savino R., Lazzaro D., Costa P., et al. Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proc. Natl. Acad. Sci. U.S.A. 96 11 (1999) 6417-6422
21. Facciabene A., Aurisicchio L., and La Monica N. Baculovirus vectors elicit antigen-specific immune responses in mice. J. Virol. 78 16 (2004) 8663-8672
22. Mennuni C., Calvaruso F., Facciabene A., Aurisicchio L., Storto M., Scarselli E., et al. Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. Int. J. Cancer 117 3 (2005) 444-455
23. Cipriani B., Fridman A., Bendtsen C., Dharmapuri S., Mennuni C., Pak I., et al. Therapeutic vaccination halts disease progression in BALB-neuT mice: the amplitude of elicited immune response is predictive of vaccine efficacy. Hum. Gene Ther. 19 7 (2008) 670-680
24. Mennuni C., Ugel S., Mori F., Cipriani B., Iezzi M., Pannellini T., et al. Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer. Cancer Res. 68 23 (2008) 9865-9874
25. Peruzzi D., Mori F., Conforti A., Lazzaro D., De Rinaldis E., Ciliberto G., et al. MMP11: a novel target antigen for cancer immunotherapy. Clin. Cancer Res. 15 12 (2009) 4104-4113
26. Dharmapuri S., Peruzzi D., Mennuni C., Calvaruso F., Giampaoli S., Barbato G., et al. Coadministration of telomerase genetic vaccine and a novel TLR9 agonist in nonhuman primates. Mol. Ther. 17 10 (2009) 1804-1813
27. Keefe D.L. Trastuzumab-associated cardiotoxicity. Cancer 95 7 (2002) 1592-1600
28. Setoguchi A., Sakai T., Okuda M., Minehata K., Yazawa M., Ishizaka T., et al. Aberrations of the p53 tumor suppressor gene in various tumors in dogs. Am. J. Vet. Res. 62 3 (2001) 433-439
29. Breen M., and Modiano J.F. Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans-man and his best friend share more than companionship. Chromosome Res. 16 1 (2008) 145-154
30. Uva P., Aurisicchio L., Watters J., Loboda A., Kulkarni A., Castle J., et al. Comparative expression pathway analysis of human and canine mammary tumors. BMC Genomics 10 1 (2009) 135
31. Felsburg P.J. Overview of immune system development in the dog: comparison with humans. Hum. Exp. Toxicol. 21 9-10 (2002) 487-492
32. Ramos I., Alonso A., Marcen J.M., Peris A., Castillo J.A., Colmenares M., et al. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response. Vaccine 26 3 (2008) 333-344
33. Zhang S., Liu Y., Fooks A.R., Zhang F., and Hu R. Oral vaccination of dogs (Canis familiaris) with baits containing the recombinant rabies-canine adenovirus type-2 vaccine confers long-lasting immunity against rabies. Vaccine 26 3 (2008) 345-350
34. Bergman P.J., McKnight J., Novosad A., Charney S., Farrelly J., Craft D., et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin. Cancer Res. 9 4 (2003) 1284-1290
35. Liao J.C., Gregor P., Wolchok J.D., Orlandi F., Craft D., Leung C., et al. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun. 6 (2006) 8
36. Bergman P.J., Camps-Palau M.A., McKnight J.A., Leibman N.F., Craft D.M., Leung C., et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 24 21 (2006) 4582-4585
37. Angelopoulou K., Zavlaris M., Papaioannou N., and Vlemmas I. Canis familiaris telomerase reverse transcriptase undergoes alternative splicing. Mamm. Genome 19 9 (2008) 647-653
38. Nasir L., Gault E., Campbell S., Veeramalai M., Gilbert D., McFarlane R., et al. Isolation and expression of the reverse transcriptase component of the Canis familiaris telomerase ribonucleoprotein (dogTERT). Gene 336 1 (2004) 105-113
39. Facciabene A., Aurisicchio L., Elia L., Palombo F., Mennuni C., Ciliberto G., et al. DNA and adenoviral vectors encoding carcinoembryonic antigen fused to immunoenhancing sequences augment antigen-specific immune response and confer tumor protection. Hum. Gene Ther. 17 1 (2006) 81-92
40. Fattori E., Aurisicchio L., Zampaglione I., Arcuri M., Cappelletti M., Cipriani B., et al. ErbB2 genetic cancer vaccine in nonhuman primates: relevance of single nucleotide polymorphisms. Hum. Gene Ther. 20 3 (2009) 253-265
41. Gallo P., Dharmapuri S., Nuzzo M., Maldini D., Cipriani B., Forni G., et al. Adenovirus vaccination against neu oncogene exerts long-term protection from tumorigenesis in BALB/neuT transgenic mice. Int. J. Cancer 120 3 (2007) 574-584